Monthly Archives: January 2022

Zymedyne Therapeutics is pleased to announce that a Mitacs Accelerate Industrial Postdoc has been awarded to Dr Ketul Patel to conduct structure-activity relationship studies and assess the molecular properties of Zymedyne’s lead molecules. Using organic synthesis and medicinal chemistry, Ketul’s work will also help develop new drugs with improved potency, specificity, and commercial potential. The Mitacs Accelerate Industrial Postdoc, together with the partnering company, provides up to three years of funding – valued at up to $60,000 per year. For more information, please visit:

Zymedyne is pleased to announce that Co-founder Dr. Chris Bladen was awarded 1st place in the “EntrepreNeuro Pitch Competition” from Campus Alberta (CAN). The CAN “Entrepeneuro” Program is a 7-week cohort-based program designed to support early-stage neuroscience projects to launch or grow their innovations. The prize money awarded will help Zymedyne with patenting costs associated with developing our novel non-opioid-based pain therapeutics platform. To learn more about the CAN Entrepreneuro program, visit: